p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Narra J
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Factors influencing histoplasmosis incidence in multidrug-resistant pulmonary tuberculosis patients: A cross-sectional study in Indonesia Khairunnisa, Selfi; Soeroso, Noni N.; Abdullah, Muntasir; Siahaan, Lambok; Eyanoer, Putri C.; Daulay, Elvita R.; Wahyuningsih, Retno; Denning, David W.
Narra J Vol. 3 No. 3 (2023): December 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v3i3.403

Abstract

Histoplasmosis is an infectious disease caused by the dimorphic fungus Histoplasma capsulatum, which, in chronic conditions, is generally difficult to distinguish from pulmonary tuberculosis based on its clinical appearance; therefore, diagnostic errors can occur. Meanwhile, the prevalence of multidrug-resistant pulmonary tuberculosis (MDR-TB) in Indonesia remains high. Study determining the incidence of histoplasmosis in MDR-TB is unavailable worldwide. The aim of this study was to determine the risk factors of histoplasmosis incidence in MDR-TB patients in Indonesia. A cross-sectional was conducted at H. Adam Malik General Hospital, Medan, Indonesia and the ELISA platform (semi-quantitative) was used to detect histoplasma antibodies. Factors associated with histoplasmosis incidence among MDR-TB were determined using a Chi-squared test. A total of 50 MDR-TB patients were included this study of which 14 of them (28%) had histoplasmosis. The majority of histoplasmosis occurred in males, in MDR-TB patients with a history of TB treatment and among who had chest x-rays with far-advanced lesions. However, statistical analyses indicated none of those factors (sex, TB treatment history, status of the lung) as well as age group, acid-fast bacillus result, Mycobacterium tuberculosis culture result, having pet, living in damp house, working in the field or plantation, having HIV infection and smoking status were associated with histoplasmosis incidence. This study highlights that the incidence of histoplasmosis is relatively high and therefore further studies are important to be conducted in Indonesia that has a high MDR-TB cases.
Effectiveness of upper arm and breathing exercises to improve inflammatory markers in severe COVID-19 patients Tarigan, Amira P.; Firdaus, Ruby; Pandia, Pandiaman; Pradana, Andika; Abdullah, Muntasir; Sinaga, Sudirman P.; Wijanarko, Wahyu; Triwahyudi, Bibit; Vera, Yeni; Maryaningsih, Maryaningsih; Eyanoer, Putri C.; Listyoko, Aditya S.
Narra J Vol. 4 No. 1 (2024): April 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i1.417

Abstract

Studies have suggested associations between inflammatory markers with the severity of coronavirus disease 2019 (COVID-19). Therefore, exercises that could reduce the level of inflammatory markers might be beneficial. The aim of this study was to determine the effect of upper arms and breathing exercises on inflammatory markers such as ferritin, lactate dehydrogenase (LDH), and C-reactive protein (CRP) in severe COVID-19 patients. A quasi-experimental with pre-test and post-test control group design was conducted among severe COVID-19 aged 18–70 years old, with or without comorbidities. Baseline data of inflammatory markers (ferritin, LDH, and CRP) were measured before the exercises and repeated post-exercise. The upper arm and breathing exercises were performed for ten days, twice a day (morning and evening) for ten minutes. A paired Student t-test was used to assess the changes in the inflammatory markers’ levels. Our data indicated that levels of ferritin and CRP were not significantly different between pre- and post-exercise. However, the level of LDH decreased significantly from 481.35 U/L to 331.80 U/L (p=0.001). This study highlights that pulmonary rehabilitation exercises might be beneficial to enhance the recovery process in severe COVID-19 patients.